Navigation Links
PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
Date:10/25/2014

DALLAS and NEW YORK, Oct. 24, 2014 /PRNewswire/ -- PlasmaTech Biopharmaceuticals, Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing patient care in critical areas, announced it has implemented a 1-for-50 reverse split of its common stock effective at the opening of trading on Friday, October 24, 2014. PlasmaTech's common stock will trade on a split-adjusted basis under new CUSIP number 72754H109 and temporary ticker symbol "ACCPD". After 20 days, the common stock will commence trading under the ticker symbol (PTBI). In addition, the Company has changed its name to PlasmaTech Biopharmaceuticals, Inc. and launched its new corporate website: www.plasmatechbio.com.

As a result of the stock split, every fifty shares of issued and outstanding PlasmaTech Bio common stock (formerly Access Pharmaceuticals stock) will be converted into one share of common stock.  Proportional adjustments will be made to the Company's options, warrants and conversion terms in convertible notes. Any fractional shares resulting from the reverse stock split will be rounded up to the next whole share.

Information to Shareholders
Stockholders who have existing stock certificates will receive written instructions by mail from the Company's transfer agent, American Stock Transfer & Trust Company.  Stockholders who hold their shares in brokerage accounts or "street name" are not required to take any action to effect the exchange of their shares. Such stockholders will be contacted by their brokers with instructions.

About PlasmaTech Biopharmaceuticals, Inc.
Formerly Access Pharmaceuticals, Inc., PlasmaTech Biopharmaceutcials, Inc. is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech Bio is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ and multiple follow-on products in development.  For more information visit, www.plasmatechbio.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for MuGard and ProctiGard, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to PlasmaTech's need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in  PlasmaTech's' Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.

Company and Media Contact:
Christine Berni
Vice President, Corporate Development
PlasmaTech Biopharmaceuticals, Inc.
(212) 786-6208


'/>"/>
SOURCE PlasmaTech Biopharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu
6. Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program
7. iCo Therapeutics Announces Advancement of Oral Amphotericin B Program
8. Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury
9. BIOREM announces additional orders for $1.7 million
10. PureTech Announces Expansion with Oversubscribed $55M Funding Round
11. Algoid Technologies, Leading Microalgae Producer, Announces New Website and Social Media Presence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 10, 2019 , ... ... add 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed journals. ... continually expanding library of more than 20 million articles, sourced from more than ...
(Date:6/11/2019)... , ... June 11, 2019 , ... ... Personalized Stem Cells Inc. (PSC) , has announced that their GMP facility ... Food and Drug Branch for manufacturing. This is an important milestone for ...
(Date:6/6/2019)... ... June 05, 2019 , ... WCCT Global, Inc ., a full-service early ... that they will be receiving 3 awards at the 2019 CRO Leadership Awards, to ... in the categories of overall Quality and Compatibility (Access to desired markets, cultural fit, ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... applications from the USPTO providing proprietary interest to our methodology, processes, and ... DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep ...
Breaking Biology Technology:
(Date:8/15/2019)... ... August 15, 2019 , ... Deep Science Ventures (DSV), a new ... a new unit dedicated to building 100 companies over the next 10 years to ... chains. , Deep Science Ventures was founded to create a better method for ...
(Date:8/14/2019)... ... August 14, 2019 , ... Join Jonathan Riek, PhD, ... on Tuesday, September 10, 2019 at 1pm EDT to learn about two common ... management. , NAFLD is the most common diffuse liver disease, with a worldwide ...
(Date:8/9/2019)... ... ... With a demand in healthcare to lower unneeded emergency room visits and provide ... in the coming years, according to a new report on the industry by market ... is a detailed look at the current state of these healthcare outlets, including the ...
Breaking Biology News(10 mins):